MFIM
INTS icon

Mesirow Financial Investment Management’s Intensity Therapeutics INTS Stock Holding History

Mesirow Financial Investment Management’s Portfolio INTS Stock Details INTS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$57.9K Hold
14,118
– – ﹤0.01% 524
2026
Q1 		$83K Buy
14,118
+4,078
+41% +$33.3K ﹤0.01% 506
2025
Q4 		$103K Buy
10,040
+2,040
+26% +$20.7K ﹤0.01% 475
2025
Q3 		$48.5K Buy
8,000
+3,600
+82% +$25.7K ﹤0.01% 549
2025
Q2 		$33.8K Buy
4,400
+2,800
+175% +$57.5K ﹤0.01% 531
2025
Q1 		$78.8K Buy
1,600
+800
+100% +$44.5K ﹤0.01% 570
2024
Q4 		$35.2K Sell
800
-967
-55% -$70.2K ﹤0.01% 584
2024
Q3 		$169K Hold
1,767
– – ﹤0.01% 556
2024
Q2 		$216K Hold
1,767
– – ﹤0.01% 466
2024
Q1 		$230K Buy
1,767
+400
+29% +$47.9K 0.01% 469
2023
Q4 		$293K Buy
+1,367
New +$144K 0.01% 436

Other funds holding INTS

KCIA
Kingsbury Capital Investment Advisors Wilmette, Illinois $118M AUM
KWM
KMT Wealth Management El Segundo, California $118M AUM 26.19% 1-Year Est. Return
SL
Sentinus LLC Oak Brook, Illinois $1.25B AUM 22.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SC
Sapient Capital Indianapolis, Indiana $7.64B AUM 51.51% 1-Year Est. Return
NCNMGF
Nano-Cap New Millennium Growth Fund Staten Island, New York $130M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Mesirow Financial Investment Management's INTS Position: Q2 2026 in Review

Mesirow Financial Investment Management held its Intensity Therapeutics (INTS) position steady in Q2 2026 at 14,118 shares worth $57.9K. The position accounts for ﹤0.01% of the portfolio, ranked #524.

Mesirow Financial Investment Management first reported a position in INTS in Q4 2023 and has held it in 11 quarters since. The position peaked at $293K in Q4 2023. 17 funds tracked by Wall St. Rank hold INTS as of Q2 2026.

  • Mesirow Financial Investment Management held 14,118 shares of Intensity Therapeutics worth $57.9K as of Q2 2026.
  • Mesirow Financial Investment Management left its Intensity Therapeutics share count unchanged in Q2 2026.
  • Intensity Therapeutics made up ﹤0.01% of Mesirow Financial Investment Management's portfolio in Q2 2026, its #524 holding.
  • Mesirow Financial Investment Management first reported a position in Intensity Therapeutics in Q4 2023 and has held it in 11 quarters since.
  • Mesirow Financial Investment Management's Intensity Therapeutics position peaked at $293K in Q4 2023.
  • 17 funds tracked by Wall St. Rank held Intensity Therapeutics as of Q2 2026.

Based on Mesirow Financial Investment Management's 13F filing for Q2 2026, filed 22 Jul 2026.